Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Exercise of Warrants and Options

10th Mar 2009 16:14

RNS Number : 6361O
Tepnel Life Sciences PLC
10 March 2009
 



Tepnel Life Sciences plc ('Tepnel' or 'the Company')

Exercise of Warrants and Options

Manchester, UK, 10 March 2009: Tepnel Life Sciences PLC (AIM: TED), the international Molecular Diagnostics and Research Products & Services group, today announces that the Board of Directors approved the issue of 5,219,444 new Ordinary Shares of 1 pence each in connection with the exercise of warrants and options as detailed below:

Warrants
Number 
Exercise Price (pence)
4,420,000
6.98
523,444
8.05

 

Options
Number 
Exercise Price (pence)
238,000
6.125
35,000
8
3,000
22

 

Application has been made by the Company for the 5,219,444 new Ordinary Shares to be admitted to the AIM market. It is expected that Admission will become effective and that dealings on AIM will commence on or around 16 March 2009.

Following admission to AIM of the new Ordinary Shares, the total number of Ordinary Shares in issue will be 249,180,970.

-End-

For further information:

Tepnel Life Sciences plc

Ben Matzilevich, CEO

Michael Slater, Group Finance Director

Carol Smith, Group Marketing Communications Manager

Tel: 0161 946 2200

Capital MS&L

Mary Clark or Catie Corcoran

Tel: +44 20 7307 5330

Seymour Pierce Limited

Mark Percy

Tom Sheldon

Christopher Wren

Tel: +44 20 7107 8000

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USAUK and France with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments. For more information please visit www.tepnel.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISCKKKDABKDKND

Related Shares:

TED.L
FTSE 100 Latest
Value8,275.66
Change0.00